Cutaneous candidiasis and chronic mucocutaneous candidiasis

Published on 18/03/2015 by admin

Filed under Dermatology

Last modified 18/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2034 times

Cutaneous candidiasis and chronic mucocutaneous candidiasis

Caroline Halverstam and Steven R. Cohen

Evidence Levels:  A Double-blind study  B Clinical trial ≥ 20 subjects  C Clinical trial < 20 subjects  D Series ≥ 5 subjects  E Anecdotal case reports

image

Cutaneous candidiasis

Cutaneous candidiasis is typically caused by Candida albicans, which exists as normal flora of human skin as well as in the gastrointestinal and genitourinary systems. Overgrowth of Candida species is suppressed by normal bacterial flora. Other Candida species occasionally cause mucocutaneous infections, the second most common being Candida tropicalis. Under certain conditions, these Candida species overgrow and become pathogens. Warmth and moisture of the intertriginous skin (axilla, inguinal folds, abdominal creases, inframammary creases), an increased skin pH, and the administration of antibiotics can disrupt the normal bacterial flora, allowing Candida to proliferate. Clinically, candidiasis presents as scaly erythematous patches with satellite papules and pustules. The diagnosis is made either microscopically, with a potassium hydroxide (KOH) preparation revealing spores and pseudohyphae, or by culture.

Management strategy

Topical antifungal agents include, but are not limited to, polyenes, azoles, allylamines, and ciclopirox olamines. Most studies required therapy twice daily for 4 weeks to ensure complete clearance in all patients. Notably, microscopic cure was often present before complete clinical clearance.

Topical corticosteroids are a source of controversy. Although the addition of corticosteroids to local antifungal therapy may reduce local inflammation in acute candidiasis, their use should be limited to 1 or 2 days because of their immunosuppressant properties.

Systemic therapy may be appropriate for cutaneous infections in immunosuppressed patients, in the setting of extensive disease not responding to topical therapy, or in patients non-compliant with topical therapy. Fluconazole 150 mg weekly appears to be as efficacious as fluconazole 50 mg daily or ketoconazole 200 mg daily. As in topical therapy, microscopic cure often precedes complete clinical clearance.

First-line therapies

image Topical antifungal A
image Topical antifungal combined with topical corticosteroids A

Second-line therapies

image Systemic azoles B